As we previously published, a multiweapon approach is needed to successfully combat SARS-CoV-2 and COVID-19 disease (Labarrere and Kassab, 2021), involving vaccines (Jin et al., 2022) especially vaccines that selectively and efficiently induce antibodies that target the SARS-CoV-2 receptor binding domain (Robbiani et al., 2020), pattern recognition proteins such as surfactant proteins A and D (Arroyo et al., 2021
N-acetyl cysteine for depressive symptoms in bipolar disordera double-blind randomized placebo- controlled trial
This months Patent Gazette features Dunads covalent PIKfyve inhibitors, Storm Therapeutics DHX9 inhibitors, and Monte Rosas CCNE1 molecular glue degraders for biomarker-defined cancers
As with many treatments in the growing regenerative space, studies in humans with exact treatments have not been done extensively yet, but what is published is promising but not proven
Hwang, S